Christopher Scott Hill - Dec 31, 2023 Form 4 Insider Report for Core Laboratories Inc. /DE/ (CLB)

Role
SVP & CFO
Signature
/s/ Mark Tattoli, Attorney-in-Fact
Stock symbol
CLB
Transactions as of
Dec 31, 2023
Transactions value $
-$244,944
Form type
4
Date filed
1/3/2024, 05:43 PM
Previous filing
Feb 21, 2023
Next filing
Feb 15, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLB Common Stock Tax liability -$245K -13.9K -16.08% $17.66 72.4K Dec 31, 2023 Direct
transaction CLB Common Stock Options Exercise $0 +36.1K +71.9% $0.00 86.2K Dec 31, 2023 Direct
holding CLB Common Stock 59 Dec 31, 2023 401(k) Plan

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLB Performance Shares Options Exercise $0 -36.1K -100% $0.00* 0 Dec 31, 2023 Common Stock 36.1K $0.00 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were awarded as restricted performance shares in February 2021, as disclosed in the Reporting Person's Form 4 filing on February 19, 2021. The Company finished in the 81st percentile of return on invested capital among the Bloomberg Peer Group at the conclusion of the performance period on December 31, 2023. Excess shares that could vest above the 75th percentile are subject to an absolute total shareholder return modifier, which was negative over the relevant performance period, thereby reducing the number of such shares eligible to vest by one-half. Therefore, the performance criteria and requirements for vesting have been satisfied at 106.25% of the target award level, and such number of shares vested on December 31, 2023.